Effect of CYP3A4 Induction and Inhibition on the Pharmacokinetics of SHR0302 in Healthy Subjects.
Sign Up to like & getrecommendations! Published in 2023 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.15733
Abstract: AIM SHR0302 is a selective Janus kinase (JAK) 1 inhibitor under clinical investigation for the treatment of rheumatoid arthritis. As SHR0302 is metabolized mainly by cytochrome P450 (CYP) 3A4, clinical studies were performed to evaluate… read more here.
Keywords: pharmacokinetics shr0302; effect; cyp3a4 induction; shr0302 healthy ... See more keywords